Data Sheet (Cat.No.T7343)

PF-04979064

Chemical Properties



CAS No. : 1220699-06-8

Formula: C24H26N6O3

Molecular Weight: 446.5

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	PF-04979064 is a potent and selective PI3K and mTOR dual kinase inhibitor, with Ki values of 0.13 nM and 1.42 nM, respectively.
Targets(IC50)	mTOR,PI3K
In vivo	PF-04979064 was tested against human class I PI3K isoforms α, γ, and δ, with PI3Kα Ki of 0.130 nM, PI3Kγ Ki of 0.111 nM, and PI3Kδ Ki of 0.122 nM.PF-04979064 was progressed to rat in vivo PK studies and exhibited robust PK profile: Vdss = 5.23 L/kg, Cl = 19.3 mL/min/kg, T1/2 = 1.85 h, and F % = 61%.

Solubility Information

Solubility	DMSO: 4.47 mg/mL (10.01 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.24 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2396 mL	11.1982 mL	22.3964 mL
5 mM	0.4479 mL	2.2396 mL	4.4793 mL
10 mM	0.224 mL	1.1198 mL	2.2396 mL
50 mM	0.0448 mL	0.224 mL	0.4479 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Cheng H , Li C , Bailey S , et al. Discovery of the Highly Potent PI3K/mTOR Dual InhibitorPF-04979064 through Structure-Based Drug Design[J]. Med.chem.commun, 2013, 1(2):139-144.